These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1350733)

  • 41. Cardiovascular variability after rilmenidine challenge: assessment of acute dosing effects by means of spectral analysis.
    Girard A; Février B; Elghozi JL
    Fundam Clin Pharmacol; 1995; 9(4):366-71. PubMed ID: 8566936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients.
    Konrady AO; Kasherininov YR; Shavarov AA; Shavarova EK; Vachrameeva NV; Krutikov AN; Smirnova EV; Shlyakhto EV
    J Hum Hypertens; 2006 Jun; 20(6):398-406. PubMed ID: 16543910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of rilmenidine on 24-h rhythmicity of blood pressure and spontaneous baroreflex sensitivity in essential hypertensive subjects.
    Finta E; Laude D; Alföldi S; Farsang C; Elghozi JL
    J Hypertens; 2006 Aug; 24(8):1619-25. PubMed ID: 16877965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rilmenidine in rosacea: a double-blind study versus placebo].
    Grosshans E; Michel C; Arcade B; Cribier B
    Ann Dermatol Venereol; 1997; 124(10):687-91. PubMed ID: 9740864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S5-10. PubMed ID: 8872294
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [New central agents in the treatment of arterial hypertension].
    Robles NR
    An Med Interna; 1999 Oct; 16(10):495-7. PubMed ID: 10603665
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term control of blood pressure by rilmenidine in high-risk populations.
    Pillion G; Fevrier B; Codis P; Schutz D
    Am J Cardiol; 1994 Dec; 74(13):58A-65A. PubMed ID: 7998587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of rilmenidine, a selective imidazoline I1 receptor binding ligand, in mild-to-moderate Thai hypertensive patients.
    Buranakitjaroen P; Kittipawong P; Koanantakul B; Piamsomboon C; Prasassarakich N; Silaraks S; Sukonthasarn A; Tiyapant A;
    J Med Assoc Thai; 2003 Oct; 86(10):903-10. PubMed ID: 14650701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bronchial effects of alpha 2-adrenoceptor agonists and of other antihypertensive agents in asthma.
    Dinh Xuan AT; Lockhart A
    Am J Med; 1989 Sep; 87(3C):34S-37S. PubMed ID: 2571293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acceptability of rilmenidine and long-term surveillance of plasma concentrations in hypertensive patients with renal insufficiency.
    Lins RL; Daelemans R; Dratwa M; Verbeelen D; Sennesael J; Brisgand B; Lameire N
    Am J Med; 1989 Sep; 87(3C):41S-45S. PubMed ID: 2782326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice.
    Jackson KL; Palma-Rigo K; Nguyen-Huu TP; Davern PJ; Head GA
    J Hypertens; 2014 Mar; 32(3):575-86. PubMed ID: 24275840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function.
    Harron DW; Hasson B; Regan M; McClelland RJ; King DJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S48-54. PubMed ID: 8642806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aspects of tolerability of centrally acting antihypertensive drugs.
    Webster J; Koch HF
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S49-54. PubMed ID: 8872299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New, modern, centrally active antihypertensive agents in the treatment of essential hypertension].
    Sevcík J; Masek K
    Cas Lek Cesk; 1999 Jun; 138(12):359-62. PubMed ID: 10566202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose-effect relationship of rilmenidine after chronic administration.
    Luccioni R; Lambert M; Ambrosi P; Scemama M
    Eur J Clin Pharmacol; 1993; 45(2):157-60. PubMed ID: 8223838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study.
    Meredith PA; Reid JL
    Am J Cardiovasc Drugs; 2004; 4(3):195-200. PubMed ID: 15134471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal excretory actions of antihypertensive agents. Effects of rilmenidine.
    Leary WP
    Am J Med; 1989 Sep; 87(3C):63S-66S. PubMed ID: 2571295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Centrally acting sympathetic inhibitors for therapy of patients with hypertension].
    Kawasaki H
    Nihon Rinsho; 1997 Aug; 55(8):2081-5. PubMed ID: 9284427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.